Abstract：
The most prevalent inflammatory arthritis and a leading contributor to disability is rheumatoid arthritis (RA). Although it may not have arrived in Europe until the 17th century, it was present in early Native American communities several thousand years ago. Exosomes released by mesenchymal stem cells (MSCs) are highly immunomodulatory due to the origin of the cell. As a cell-free therapy, MSCs-exosomes are less toxic and elicit a weakened immune response than cell-based therapies. Exosomal noncoding RNAs (ncRNAs) are closely associated with a number of biological and functional facets of human health, especially microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). Various exo-miRNAs and lncRNAs such as HAND2-AS1, miR-150-5p, miRNA-124a, and miR-320a lodged with MSC could be appropriate therapeutic ways for RA treatment. These MSC-derived exosomes affect RA disorders via different molecular pathways such as NFK-β, MAPK, and Wnt. The purpose of this review is to review the research that has been conducted since 2020 so far in the field of RA disease treatment with MSC-loaded exo-miRNAs and exo-lncRNAs.
摘要：
最普遍的炎性关节炎和导致残疾的主要因素是类风湿性关节炎(RA)。虽然它可能直到17世纪才到达欧洲，它存在于几千年前的早期美洲原住民社区。间充质干细胞（MSC）释放的外泌体由于细胞的起源而具有高度免疫调节性。作为一种无细胞疗法,与基于细胞的疗法相比,MSC-外泌体毒性较小并且引起减弱的免疫应答。外来体非编码RNA（ncRNAs）与人类健康的许多生物学和功能方面密切相关。特别是microRNA（miRNAs）和长链非编码RNA（lncRNAs）。各种exo-miRNAs和lncRNAs，如HAND2-AS1，miR-150-5p，miRNA-124a,和miR-320a与MSC一起可能是RA治疗的合适治疗途径。这些MSC来源的外泌体通过不同的分子途径如NFK-β、MAPK,Wnt。这篇综述的目的是回顾自2020年以来迄今为止在RA疾病治疗领域中使用MSC负载的exo-miRNA和exo-lncRNA进行的研究。
